Literature DB >> 32470546

Celastrol ameliorates acute liver injury through modulation of PPARα.

Qi Zhao1, Ping Tang2, Ting Zhang2, Jian-Feng Huang2, Xue-Rong Xiao1, Wei-Feng Zhu3, Frank J Gonzalez4, Fei Li5.   

Abstract

Celastrol, derived from the roots of the Tripterygium Wilfordi, has attracted interest for its potential anti-inflammatory and lipid-lowering activities. In the present study, the protective effect of celastrol on carbon tetrachloride (CCl4)-induced acute liver injury was investigated. Celastrol improved the increased transaminase activity, inflammation, and oxidative stress induced by CCl4, resulting in improved metabolic disorders found in mice with liver injury. Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor α (PPARα) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARα antagonist GW6471. Mechanistically, PPARα deficiency potentiated CCl4-induced liver injury through a deoxycholic acid (DCA)-EGR1-inflammatory factor axis. These data demonstrate a novel role for celastrol in protection against acute liver injury through modulating PPARα signaling.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Acute liver injury; Celastrol; LC-MS; Metabolomics; PPARα

Mesh:

Substances:

Year:  2020        PMID: 32470546      PMCID: PMC7377972          DOI: 10.1016/j.bcp.2020.114058

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  37 in total

Review 1.  Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer.

Authors:  Radhamani Kannaiyan; Muthu K Shanmugam; Gautam Sethi
Journal:  Cancer Lett       Date:  2010-12-17       Impact factor: 8.679

2.  Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

Authors:  Sébastien Dharancy; Mathilde Malapel; Gabriel Perlemuter; Tania Roskams; Yang Cheng; Laurent Dubuquoy; Philippe Podevin; Filoména Conti; Valérie Canva; David Philippe; Luc Gambiez; Philippe Mathurin; Jean-Claude Paris; Kristina Schoonjans; Yvon Calmus; Stanislas Pol; Johan Auwerx; Pierre Desreumaux
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

3.  Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.

Authors:  Mengjie Hu; Qiang Luo; Gulimiran Alitongbieke; Shuyi Chong; Chenting Xu; Lei Xie; Xiaohui Chen; Duo Zhang; Yuqi Zhou; Zhaokai Wang; Xiaohong Ye; Lijun Cai; Fang Zhang; Huibin Chen; Fuquan Jiang; Hui Fang; Shanjun Yang; Jie Liu; Maria T Diaz-Meco; Ying Su; Hu Zhou; Jorge Moscat; Xiangzhi Lin; Xiao-Kun Zhang
Journal:  Mol Cell       Date:  2017-04-06       Impact factor: 17.970

4.  Metabolic Activation of Myristicin and Its Role in Cellular Toxicity.

Authors:  Xu Zhu; Yi-Kun Wang; Xiao-Nan Yang; Xue-Rong Xiao; Ting Zhang; Xiu-Wei Yang; Hong-Bo Qin; Fei Li
Journal:  J Agric Food Chem       Date:  2019-04-04       Impact factor: 5.279

5.  c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver.

Authors:  Duarte M S Ferreira; Marta B Afonso; Pedro M Rodrigues; André L Simão; Diane M Pereira; Pedro M Borralho; Cecília M P Rodrigues; Rui E Castro
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

Review 6.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  S Mandard; M Müller; S Kersten
Journal:  Cell Mol Life Sci       Date:  2004-02       Impact factor: 9.261

Review 7.  Acylcarnitines--old actors auditioning for new roles in metabolic physiology.

Authors:  Colin S McCoin; Trina A Knotts; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2015-08-25       Impact factor: 43.330

8.  Fenofibrate A peroxisome proliferator activated receptor-α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats.

Authors:  Doaa I Mohamed; Ahmed A M Elmelegy; Lubna F A El-Aziz; Hala S Abdel Kawy; Abeer A Abd El-Samad; Omnyah A El-Kharashi
Journal:  Eur J Pharmacol       Date:  2013-10-17       Impact factor: 4.432

9.  Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway.

Authors:  Yun Zhang; Hongli Guo; Hozeifa M Hassan; Ping-Ping Ding; Yijing Su; Yuming Song; Tao Wang; Lixin Sun; Luyong Zhang; Zhenzhou Jiang
Journal:  J Appl Toxicol       Date:  2016-04-12       Impact factor: 3.446

10.  Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis.

Authors:  Ling Guo; Shi Luo; Zhengwu Du; Meiling Zhou; Peiwen Li; Yao Fu; Xun Sun; Yuan Huang; Zhirong Zhang
Journal:  Nat Commun       Date:  2017-10-12       Impact factor: 14.919

View more
  3 in total

Review 1.  Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms.

Authors:  Mengzhen Li; Faren Xie; Lu Wang; Guoxue Zhu; Lian-Wen Qi; Shujun Jiang
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

2.  Mechanism of hydroxysafflor yellow A on acute liver injury based on transcriptomics.

Authors:  Xiangmei Hou; Ziying Zhang; Yuehong Ma; Rong Jin; Bing Yi; Dongdong Yang; Lijie Ma
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 3.  Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications.

Authors:  Pushkaraj Rajendra Wagh; Preshita Desai; Sunil Prabhu; Jeffrey Wang
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.